Taiwan Advanced Nanotech Inc. (6797) fair value: what the stock is really worth
As of Oct 8, 2026: fair value of Taiwan Advanced Nanotech Inc. TWD 15.92, price TWD 12.30, upside +29.4%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range 10.50 TWD – 225.08 TWD · fair‑value band 10.51 TWD – 19.90 TWD · the 12.30 TWD price screens below the 15.92 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Taiwan Advanced Nanotech in your weekly email
Every Wednesday you see whether Taiwan Advanced Nanotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Taiwan Advanced Nanotech Inc. engages in the development, manufacturing, and sales of various functional nanoparticles and automated nucleic acid extraction equipment in Taiwan.
Show more
Taiwan Advanced Nanotech Inc. engages in the development, manufacturing, and sales of various functional nanoparticles and automated nucleic acid extraction equipment in Taiwan. The company provides automated extraction instruments; nucleic acid extraction kit that extracts DNA/RNA from samples of blood, cell, tissue, plant, bacteria, virus, etc.; consumables, such as spin tips and deep well plates; filling line systems; and molecular biology reagents. It also provides OEM/ODM services. The company was founded in 2004 and is based in Taoyuan City, Taiwan.
Stock analysis
Taiwan Advanced Nanotech Inc. (6797) currently trades at 12.30 TWD, while our model-based Fair Value estimate is 15.92 TWD, implying the stock looks roughly 22.7% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 10.51 TWD (bear) to 19.90 TWD (bull), the price of 12.30 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Taiwan Advanced Nanotech Inc. reported revenue of 154M TWD in FY2025 versus 1.9B TWD in FY2021, a compound −46.8%/yr. Reported net income was −227M TWD in FY2025.
Key figures
Market cap 370M TWD (≈ $11.6M) · P/S ratio 2.03 · EPS (TTM) −7.14 TWD · Net margin −147% · Return on equity −27.8% · Return on assets (EBIT) 0.6% · Operating margin −143% · Revenue (TTM) 171M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 29%, 6797 screens cheaper than that median.
Fair Value models
Bear 10.51 TWDFair Value 15.92 TWDBull 19.90 TWD
Price 12.30 TWD · Upside +29.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−21.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−51.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−38.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
46.4% (2020) → −150.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Taiwan Advanced Nanotech Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 325 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside+29.4% · Top 25%
Profitability
Return on assets−13.1% · Bottom 25%
Net margin (TTM)−126.6% · Bottom 25%
Operating margin (TTM)−143.4% · Bottom 25%
Growth and dividend
Revenue growth24.2% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Taiwan Advanced Nanotech Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6797
Frequently asked questions
Is Taiwan Advanced Nanotech Inc. (6797) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 15.92 TWD versus a price of 12.30 TWD, about +29% upside (undervalued).
What is the fair value of 6797?
Our model-based fair value for Taiwan Advanced Nanotech Inc. is 15.92 TWD (as of Oct 3, 2026), built from audited fundamentals. The current price: 12.30 TWD.
What is the quality score of 6797?
Taiwan Advanced Nanotech Inc. has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Taiwan Advanced Nanotech Inc. (6797)?
Our model-based price target is the fair value of 15.92 TWD (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 10.51 TWD, optimistic scenario 19.90 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Taiwan Advanced Nanotech Inc. stock forecast for 2026?
Our models put fair value at 15.92 TWD, about +29% upside versus a price of 12.30 TWD (undervalued). Cautious scenario 10.51 TWD, optimistic scenario 19.90 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Taiwan Advanced Nanotech Inc. (6797)?
Taiwan Advanced Nanotech Inc. reported trailing-twelve-month revenue of about 171M TWD (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Taiwan Advanced Nanotech Inc. (6797)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Taiwan Advanced Nanotech Inc. it is 15.92 TWD per share (as of Oct 3, 2026), against a price of 12.30 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Taiwan Advanced Nanotech Inc. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 6797 trades below its calculated fair value: price 12.30 TWD, fair value 15.92 TWD, a gap of about +29% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6797?
No. The price is what the market pays today (12.30 TWD); the fair value is what the company's own numbers justify (15.92 TWD). For Taiwan Advanced Nanotech Inc. the two are 3.62 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Taiwan Advanced Nanotech Inc. worth?
The market values Taiwan Advanced Nanotech Inc. at about 370M TWD (market capitalisation, as of Oct 3, 2026). Per share that is 12.30 TWD; our models calculate a fair value of 15.92 TWD per share.
What do the bullish and bearish scenarios say about 6797?
Our models span a range for Taiwan Advanced Nanotech Inc.: cautious scenario 10.51 TWD, base 15.92 TWD, optimistic 19.90 TWD per share (as of Oct 3, 2026, price 12.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Taiwan Advanced Nanotech Inc. (6797)?
Balance-sheet figures for Taiwan Advanced Nanotech Inc. (as of Oct 3, 2026): return on equity −27.8%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 6797 from its 52-week high?
Taiwan Advanced Nanotech Inc. trades at 12.30 TWD, about 35% below its 52-week high of 18.90 TWD and 17% above the low of 10.50 TWD (as of Oct 8, 2026). Distance from the high says nothing about value: that is what the fair value of 15.92 TWD is for.
Which stocks are comparable to Taiwan Advanced Nanotech Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Taiwan Advanced Nanotech Inc. stock attractive at the current price?
The data as of Oct 3, 2026: price 12.30 TWD, calculated fair value 15.92 TWD (+29%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6797 calculated?
We run Taiwan Advanced Nanotech Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 15.92 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.6 % above its aggregate fair value. Taiwan Advanced Nanotech Inc. currently trades 23 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Taiwan Advanced Nanotech Inc. (6797)?
The closing price on Oct 8, 2026 was 12.30 TWD. Our model-based fair value is 15.92 TWD, about +29% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Taiwan Advanced Nanotech Inc. right now?
A fairly wide model range (10.51 TWD to 19.90 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Taiwan Advanced Nanotech Inc.
How large is the market capitalisation of Taiwan Advanced Nanotech Inc. (6797)?
The market capitalisation of Taiwan Advanced Nanotech Inc. is 370M TWD (≈ $11.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Taiwan Advanced Nanotech Inc. (6797)?
The price-to-sales ratio of Taiwan Advanced Nanotech Inc. is 2.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Taiwan Advanced Nanotech Inc. (6797)?
Earnings per share at Taiwan Advanced Nanotech Inc. are −7.14 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Taiwan Advanced Nanotech Inc. (6797)?
The net margin of Taiwan Advanced Nanotech Inc. is −147% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Taiwan Advanced Nanotech Inc. (6797)?
The return on equity (ROE) of Taiwan Advanced Nanotech Inc. is −27.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Taiwan Advanced Nanotech Inc. (6797)?
On an EBIT basis the return on assets of Taiwan Advanced Nanotech Inc. is 0.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Taiwan Advanced Nanotech Inc. (6797)?
The operating margin of Taiwan Advanced Nanotech Inc. is −143% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Taiwan Advanced Nanotech Inc. (6797)?
Revenue at Taiwan Advanced Nanotech Inc. is growing +24.2% versus a year earlier (3y avg −51.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Taiwan Advanced Nanotech Inc. (6797) generate?
The free cash flow of Taiwan Advanced Nanotech Inc. is −23.4M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Taiwan Advanced Nanotech Inc. (6797) carry?
The net debt of Taiwan Advanced Nanotech Inc. is 36.8M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Taiwan Advanced Nanotech Inc. in the live analysis
One click puts Taiwan Advanced Nanotech Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
